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Creating an epigenetic toolbox to study pediatric sarcomas 
 
 
 
Abstract 
 
 
Soft tissue and bone malignancies that affect children and young adults frequently have a poor 
prognosis and a limited set of therapeutic options. A better understanding of their molecular 
pathogenesis would give us a chance to improve the treatment, by making it more specific and less 
toxic than the generic chemo and radiotherapy. Recently, it has become clear that the chromatin 
status of cancer cells is essential for the development of these malignancies but the study of the 
epigenome remains technically difficult and frequently elusive. The purpose of this work is to help 
overcome this difficulty by creating a set of tools tailored to study chromatin modifications and 
their effect on tumor biology. In particular, the aim of our work is to adapt CRISPR-Cas9 
technology, which has already revolutionized genome editing in the last decade, toward the study of 
epigenetic events. 
 
 
 
Introduction 
 
 
Pediatric sarcomas – there is still so much to discover 
 
Sarcomas are a heterogeneous group of soft tissue and bone neoplasms. They are rare tumors (only 
1% of all malignancies), but they affect children and young adults with higher frequency and their 
mortality remains excessively elevated (metastatic cases have a five-year survival rate of 20-30%) 
(1). Current treatments are based on aggressive surgery, chemotherapy, and radiations. The poor 
outcome of these cancers underlines the concrete necessity to find other treatments, targeting more 
specific mechanisms of the tumors. In this context, an interesting direction of research is pointing 
toward epigenetic modifications. 
 
In fact, an important subset of these pediatric sarcomas, including Ewing sarcoma, synovial 
sarcoma, rhabdomyosarcoma and dermatofibrosarcoma, is characterized by unique chromosomal 
translocations, which lead to the expression of a fusion protein that in most cases functions as an 
aberrant transcription factor. Whereas these translocations have a wide range of effects on the 
transcriptome, there is an increasing body of evidence linking their activity to epigenetic 
modifications.  
For example, in synovial sarcoma the inhibition of histone deacetylase (HDAC) can disrupt the 
oncoprotein complex, leading to apoptosis (2). It has also been demonstrated that synovial sarcoma 
translocation interacts with human BRM protein, that modulates chromatin remodeling (3). In 
another example, several links have been observed between the EWS-FLI-1 fusion protein and the 
epigenetic activity of Ewing sarcoma cells, including EWS-Fli1-mediated inhibition of p300-
dependent acetylation of p53, which blocks apoptosis and inhibition of HDAC mediated 
deacetylation that can lead to decreased tumor growth (4,5). 
 
In summary, better comprehension of these mechanisms could lead to novel therapeutic strategies 
in pediatric sarcomas that may significantly improve the outcome of patients, which is currently 
unsatisfactory. 
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CRISPR-Cas9 system – a new era for (epi)genetic manipulation 
 
Genetic defects linked to disease and cancer have been studied for a very long time thanks to 
constant improvement of the available technology. In particular, the human genome project in the 
last 40 years has decoded the whole human genetic information and allowed the development of 
efficient research tools, including SNP arrays, low cost genome sequencing and high throughput 
screening techniques (6). 
 
Much less understood are chemical modifications of genomic DNA that do not affect its sequence 
but have a major impact on its function by modifying its structure and thereby constituting a 
separate layer of activity. These modifications and the machinery that implements them are termed 
the epigenome. This epigenetic control is influenced by the environment, is hereditable, and is 
exploited by cancer cells; its importance therefore cannot be overstated. However, the epigenome 
has been an unexplored landscape largely for technical reasons, until the discovery of genome 
editing tools, including CRISPR and TALENs, allowed a technological leap forward.  
 
Among the different genome editing tools, CRISPR-Cas9 technology has emerged as the most 
efficient and user-friendly and therefore we elected it to use it in our work (7,8). 
Discovered in 1987 in Japan, RNA guided Cas9 nuclease is characterized by clustered regularly 
interspaced short palindromic repeats (CRISPR), and acts in the microbial adaptive immune system. 
Bacteria take advantage of these repeated sequences to recognize and destroy foreign DNA coming 
from phages and other sources (9). 
CRISPR-Cas9 is composed of two essential elements: a Cas9 nuclease that cuts DNA, and a small 
guide RNA (gRNA) that directs the enzyme to a specific sequence of the genome (7) (Figure 1, left 
panel). 
 
 
 
Figure 1, modified from Ledford, Nat News. 2016	(7) - CRISPR-Cas9: broken scissors and epigenetic modulator 
A schematic view of the catalytically inactive Cas9 (dCas9) coupled with an epigenetic module that can activate or 
repress gene expression.  
 
 
Despite the fact that this endonuclease was discovered in the eighties, the scientific community 
started to take advantage of its power to edit the genome only in the last few years. 
The biggest advantage of CRISPR-Cas9 over all the other methods is the simplicity of the system. 
In fact, it allows targeted cleavage of DNA and can be used to induce any modification at the 
genomic level. Furthermore with a small modification the tool can be repurposed to accomplish the 
same effect at the epigenetic level (Figure 1, right panel). 
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Stanley Qi, from Stanford University in California, made the first modification necessary to achieve 
this goal: the abrogation of Cas9 nuclease activity with retention of the DNA/RNA binding 
properties. Subsequently, the next leap forward came in 2015, when a group from Duke University 
published a system to use dCas9 coupled with an epigenetic module. 
In fact, the deactivated Cas9 (dCas9) can be fused with other enzymes that affect the transcriptional 
activity and/or the epigenetic status of DNA on a chosen sequence of the genome, with 
unprecedented precision and specificity. Thus, it is possible to modulate the activity of selected 
genes by modifying their epigenetic status (7,9,10). 
 
 
Project goals – and a little hope 
 
The aim of our project is to create a coherent and single-plasmid epigenetic toolbox using CRISPR-
Cas9 technology, which will allow us to simplify and speed up the study of pediatric sarcoma 
pathogenesis and biology. The use of our toolbox could help the scientific community to progress in 
pediatric sarcoma understanding and we hope that this will push forward the development of more 
targeted treatments. The toolbox is composed of six of the more relevant epigenetic modules for 
pediatric sarcomas: VP64, P300, Tet1, DNMT3a, HDAC and KRAB (2,4,5,11–16) (Table 1). 
 
 
 
Results 
 
 
The universal vector 
 
The first goal we wanted to accomplish was to develop a homogeneous system to deliver our 
epigenetic modules to the cells. To do that, we used a Lentivirus based method, which is one of the 
most efficient ways to transfer genetic material in vivo. In fact, the main advantages of VSV 
pseudotyped Lentiviruses are high efficiency of transduction, wide tropism, the capacity to infect 
cells independently of their mitotic state, and the ability to package more than one transcriptional 
unit in one single payload. 
 
In particular, we wanted to base our common system on the Feng Zhang CRISPR-Cas9 second-
generation vector, which is a single plasmid capable of delivering both the dCas9 module and the 
guide RNA (17). The plasmid contains two long terminal repeats (LTR) regions, which enclose the 
spCas9 (replaced with a dCas9), a spacer (used to facilitate the cloning of the gRNA) and a 
Puromycin selection marker (Puro) (Figure 2). 
 
In summary, we wanted to build a unified and efficient system of all these tools, which until now, 
taken all together, had a heterogeneous delivery method with a non-coherent design.  
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Figure 2 - The universal vector 
Reengineering of LentiCRISPR second-generation plasmid (17). The spCas9 module, driven by the elongation factor 
1alpha promoter (EFS), is substituted by an epigenetic-module-dCas9 fusion protein. The ability to add a guide RNA in 
a separate transcriptional unit (U6 promoter) remains unchanged. 
 
 
Red Puro – And there was light 
 
In a viral infection the ratio between transforming units (TU) and the number of cells (multiplicity 
of infection, MOI) determines both the number of infection events and how many provirus copies 
are incorporated within the cell genome. Thanks to the Poisson distribution equation, these 
variables can be calculated (18). Therefore, to have a controlled experiment for these two 
parameters it is necessary to measure the TU of the virus preparation. To accomplish this task one 
of the most convenient methods is based on the use of a fluorescent marker in a FACS analysis 
setting. Therefore, we exchanged the Puro cassette with the red-fluorescence-puromycin fused 
sequence (RedPuro), to add a fluorescent signal to the system. Protein domains are modular and 
tend to remain functional, even if embedded in a different amino acid sequence. In this case, it has 
been proved that by fusing the red fluorescent protein (RFP) in-frame to the Puro cassette, both 
enzymatic activities are retained (19) (Figure 3). The RedPuro is embedded in the same 
transcriptional unit of spCas9, rendered bi-cistronic by the 2A peptide (2AP) (20). This design 
reduces the payload size, which has the advantage of maintaining good packaging efficiency.  
 
LentiCRISPR v2 
LTR 
U6 
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EFS Promoter 
spCAS9 
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LTR 
AMPr LTR 
Guide RNA 
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module 
LTR 
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Figure 3 – LentiCRISPR second-generation RedPuro design 
Design of the sticky end cloning (BamHI, BsiWI) used to modify the Puro cassette with a RedPuro. We inserted 
RedPuro into an intermediate vector (pCrv2Blunt, Invitrogen) before moving it into the LentiCRISPR second-
generation plasmid. The dotted arrow indicates the cloning site. The continuous arrow shows the excision of the insert. 
The right panel represents the final clone. 
 
 
To test the expression of the RedPuro cassette we transfected LentiCRISPR second-generation 
RedPuro plasmid into the HEK 293T cells and verified the expression of RFP fused with Puro by 
using an epifluorescent microscope. (Figure 4) 
 
 
 
 
Figure 4 - HEK 293T transfected with LentiCRISPR second-generation RedPuro 
The image shows four different fields acquired in bright light merged with the epifluorescent 564 nm signal. The scale 
unit is shown in the first panel and represents 100 µm. 
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Epigenetic modules – the gateway to change 
 
To have a complete toolbox, we included six of the most relevant epigenetic modules used to 
regulate gene expression. We targeted DNA methylation as well as histone acetylation and 
methylation, in addition to generic transcriptional activation. 
 
More specifically, we targeted DNA methylation, by including in the toolbox Tet1 and DNMT3a, 
which respectively demethylate and methylate DNA (11,12). We also targeted histone 
modifications, namely acetylation, deacetylation (P300 and HDAC) (13,14) and methylation 
(KRAB) (15). Finally, we added to the toolbox a transcriptional activator that acts by recruiting 
different cofactors (VP64) (13,16) (Table 1). 
 
Table 1 - Epigenetic modules 
The table represents the list of the epigenetic toolbox components. VP64, P300 and Tet1 activate, instead DNMT3a, 
HDAC and KRAB repress transcription. Each tool affects the chromatin in a different way, including a direct effect on 
the DNA or through a modification of the histones, as well as by recruiting co-factors. 
 
 
In summary, our work consists of exchanging the spCas9 with the dCas9 epigenetic modules in the 
LentiCRISPR second-generation RedPuro vector (Figure 3). These tools are compatible with the 
original strategy to clone the gRNAs between BsmBI sites, developed by Zhang et Al. (21). 
 
In the next sections we will detail the strategies and challenges we had to face to accomplish this 
goal.  
 
 
 
 
Epigenetic	Module	 Activity	 Mechanism	
VP64	 Activation	of	transcription	 Sequential	recruitment	of	
co-factors	
P300	 Activation	of	transcription	 Histone	acetylation	
Tet1	 Activation	of	transcription	 DNA	demethylation	
DNMT3a	 Repression	of	transcription	 DNA	methylation	
HDAC	 Repression	of	transcription	 Histone	deacetylation	
KRAB	 Repression	of	transcription	 Histone	methylation	and	
deacetylation	
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VP64 and P300 – the entry-level job 
 
The cloning of VP64 and P300 had a similar design and will be detailed in the following sections. 
 
 
VP64 
 
Concerning VP64 module, our strategy was to insert VP64-dCas9 into the backbone of the 
LentiCRISPR second-generation RedPuro, using XbaI and BamHI restriction sites (Figure 5). 
However, because there is an extra BamHI site in the VP64 sequence, we first had to destroy it by 
mutation (A4255C), leaving the translation unchanged by taking advantage of the genetic code 
redundancy. 
 
To change the nucleotide sequence, we used the PCR technique. Briefly, we opted to use as a 
template the VP64-dCas9 vector from Addgene (ID 61425) to obtain an amplicon. Then we 
designed two pairs of primers generating two different amplicons, harboring the mutation in an 
overlapping sequence common to both products (see Figure 5, panels A and B). 
By using these two molecules as a template, we joined them together in the final mutated product 
by a second PCR amplification using only the external primers (see Figure 5, panel C). 
We used a proofreading Taq-polymerase to avoid eventual out-of-frame mutations introduced by 
the Taq-polymerase propensity to add an extra dATP at the 3’end of the amplicon. 
 
Figure 5 - PCR strategy to delete BamHI site 
VP64dCas9 PCR used to mutate the adenine in position 4255 from the ATG to a cytosine (A4255C). Panel A: First 
PCR reaction based on 5’ part of amplicon. 5’ primer adds XbaI restriction site, 3’ primer inserts A4255C mutation. 
Panel B: Second PCR reaction based on 3’ part of the amplicon. 5’ primer inserts A4255C mutation, 3’ primer adds 
BamHI restriction site. Panel C: Third PCR reaction that merges the two amplicons resulting from the previous PCRs. 
The blue star shows that the result of the third PCR contains the desired mutation. 
 
The external primers also harbored an extra sequence introducing the corresponding XbaI and 
BamHI sites. The direct PCR cloning could be problematic because the digestion of a PCR product 
is very inefficient, especially with large amplicons (22). Therefore, the final product was cloned 
into an intermediate vector (pCRv2Blunt), designed for Blunt-end cloning. In the last step we 
prepared both the backbone and the insert by digestion with the corresponding restriction sites and 
gel-purification. Finally, the two molecules were pasted together by a fast ligation reaction, 
following a homemade protocol (see Materials and methods). 
 
A. B. 
C. 
VP64dCas9 
G GATCC = BamHI site 
G GCTCC ≠ BamHI site  
XbaI	-	
-	BamHI	
XbaI	-	
-	BamHI	
XbaI	 BamHI	
XbaI	 BamHI	
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Figure 6 - Design for LentiCRISPR second-generation RedPuro VP64 
To clone the VP64-dCas9 module we used as the backbone the LentiCRISPR second-generation RedPuro plasmid and 
as the insert the amplicon VP64-dCas9, cloned from an intermediate vector (pCrv2Blunt). The restriction sites used for 
ligation are indicated in the figure. The dotted arrow points the cloning site. The continuous arrow indicates the excision 
of the insert. The right panel represents the final clone. 
 
 
P300 
 
To clone the P300-dCas9 module, we used a strategy identical to the one outlined in the previous 
section, with the following differences (Figure 7): 
• The template was taken from Addgene (ID 61357); 
• The internal restriction site to be mutated was BglII (C4907T); 
• The flanking restriction sites of the insert were BglII and SpeI, harboring a compatible 
overhang with respectively BamHI and XbaI; this design was necessary because there were 
multiple internal BamHI and XbaI sites. 
 
The P300 sequence harbors an internal BsmBI site as well (see Figure 8). Therefore to clone the 
gRNA we have to modify the standard Zhang protocol (21), as outlined below: 
Instead of using a pair of primers to be annealed and originate the BsmBI overhangs, a synthetic 
double strand DNA of approximately 700 bp should be synthesized with the following design 
(Figure 8, panel B): 
• At the beginning the gRNA sequence; 
• Followed by the part of dCAS9 lost after digestion of LentiCRISPR second-generation 
RedPuro P300 with BsmBI; 
• A strategically placed BsmBI at both ends of the sequence, which recreates the sticky ends 
compatible with the digested vector. 
The gBlocks fragment should be intermediate-cloned with a Blunt-end vector, such as PCRv2Blunt, 
then excised with BsmBI and finally cloned into the p300-dCas9 module, as well as digested with 
BsmBI (Figure 8). 
LentiCRISPR_v2_RedPuro 
LTR 
U6 
Spacer 
EFS Promoter 
 
 
RedPuro 
 
LTR 
AMPr 
spCas9	
LentiCRISPR_v2_RedPuro_VP64 
LTR 
U6 
Spacer 
EFS Promoter 
 
 
RedPuro 
 
LTR 
AMPr 
dCas9	
VP64	
XbaI	
BamHI	
XbaI	BamHI	
spCas9	
VP64-dCas9	(from	pCrv2Blunt)	
9		 	
 
Figure 7 - Design for LentiCRISPR second-generation Red Puro P300 
To clone the P300-dCas9 module we used as the backbone the LentiCRISPR second-generation RedPuro plasmid and 
as the insert the amplicon p300-dCas9, cloned from an intermediate vector (pCrv2Blunt). We took advantage of the 
complementarity of restriction enzymes (XbaI-SpeI, BamHI-BglII). The dotted arrow indicates the cloning site. The 
continuous arrow shows the excision of the insert. The right panel represents the final clone. 
 
 
 
Figure 8 - gRNA cloning strategy variation for P300 
Panel A: Map of LentiCRISPR second-generation RedPuro P300 showing an extra BmsBI site inside the coding 
sequence. Panel B: An alternative design to clone a gRNA, using a synthetic double strand DNA. In red, an example of 
gRNA sequence, which has to be modified according to the target. 
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Tet1 – when the going gets tough… 
 
To clone the Tet1-dCas9 module, we used a similar strategy to the one outlined in the VP64 section, 
with the following differences: 
• The template was taken from Addgene (ID 84475); 
• There was no internal restriction site to be mutated; 
• The flanking restriction sites of the insert were XbaI and BglII, harboring a compatible 
overhang with BamHI. This design was necessary because there were multiple BamHI 
internal sites. 
 
The amplicon was cloned in an intermediate vector and processed exactly as described in the VP64 
section (Figure 9). 
 
Figure 9 - Design for LentiCRISPR second-generation Red Puro Tet1 
To clone the Tet1-dCas9 module we used as the backbone the LentiCRISPR second-generation RedPuro plasmid and as 
the insert the amplicon Tet1-dCas9, cloned from an intermediate vector (pCrv2Blunt). We took advantage of 
complementarity of restriction enzymes (BamHI-BglII). The dotted arrow indicates the cloning site. The continuous 
arrow shows the excision of the insert. The right panel represents the final clone. 
 
 
During the screening step, Tet1 cloning presented an unexpected challenge. The electroporation 
consistently generated a large number of apparently false positive colonies. In fact, the standard 
PCR-based screening of several tens of randomly selected colonies did not detect any real positive 
(as shown in Figure 10, Panel A). By controlling the PCR screening, we discovered that the reaction 
with those particular primers and template was not compatible with a successful amplification. For 
this reason, instead of trying to optimize the reaction, we switched to the old “cracking colonies” 
method, which does not require any kind of previous manipulation, such as PCR amplification or 
DNA digestion. Briefly, the method consists of loading on the agarose gel directly a lysated 
bacterial colony (see Materials and methods). After the run, these samples reveal the presence of a 
supercoiled plasmid DNA as single or multiple bands. By comparing this profile with an empty 
backbone reference, it is possible to select any candidate showing a slower mobility on the gel. This 
method greatly simplifies the screening process and reduces the chance of showing false negatives 
signals (see Figure 10, Panel B). 
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Figure 10 – Screening of candidate clones for Tet1 module 
Panel A: an example of negative PCR-based screening. The large bands on the bottom of the gel represent the 
unincorporated primers. There are no amplicons compatible with the expected size. Panel B: Cracking method 
screening showing a positive candidate (blue circle) with a slower electrophoretic mobility compared to the negative 
clones, due to the presence of the correctly cloned insert. 
 
 
DNMT3a, HDAC and KRAB – …the tough get going 
 
The remaining cloning projects, for DNMT3a, HDAC and KRAB modules, were initially 
unsuccessful and required a careful troubleshooting process. We speculated that the main problem 
we were facing was due to a toxic effect of these dCas9 modules. In fact, the LTR promoter 
contains bacteria cryptic sequences, which allow the expression of the dCas9-fused protein inside 
the bacterial cells. This event leads to the creation of an environment that favors recombinant clones 
(23). We also considered that another potential problem was the large size of these three modules, 
therefore all together creating a molecular perfect storm. Based on both these conjectures, we 
devised a multi-step mitigation strategy: 
• The origin of replication of LentiCRISPR second-generation RedPuro is based on PUC18, 
which at 37°C determines a high copy number of plasmids, while below 30°C drops to a 
lower one (24). Therefore, we proceeded with a clonal selection at room temperature instead 
of 37°C to mitigate the toxic effect; 
• It has been reported in the literature that an inter-chain ligation between two backbones 
DNA strands generates a circular plasmid containing repetitive sequences, which are 
subsequently removed by the enzymatic apparatus of the bacterial cells (25). Therefore, we 
reasoned that dephosphorylation of the backbone would help to reduce recombinant clones, 
by preventing the ligation between them; 
• It is well known that the size of the insert reduces the efficiency of the cloning. We took 
advantage of some unique internal restriction sites in dCas9, which allow us to split the 
insert in two smaller fragments. Therefore we proceeded with a two-step cloning procedure 
(see Figures 11, 12, 13). 
 
A.	
B.	
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Based on this strategy, we modified the cloning design used for VP64, P300 and Tet1 as detailed in 
the following sections.  
 
 
DNMT3a 
 
To clone the DNMT3a-dCas9 module, we used a similar strategy to the one outlined in the Tet1 
section, with the following differences: 
• The template was taken from Addgene (ID 84476);  
• The insert was divided into two pieces 
o The first fragment was cloned with XbaI, EcoRV restriction enzymes in the 
corresponding sites of LentiCRISPR second-generation RedPuro plasmid (Figure 
11); this construct was used as a backbone to clone the second fragment (see next 
point) 
o The second fragment was cloned using EcoRV, BglII for the insert, and EcoRV, 
BamHI for the backbone taken from the previous cloning; 
• To further decrease the background, we digested the ligation product before electroporation 
with BglII and BamHI restriction enzymes. We reasoned that a correct ligation between 
these compatible overhangs would destroy both sites, therefore the digestion would linearize 
only recombined constructs, making them unable to transform bacterial cells.  
 
 
 
Figure 11 - Design for LentiCRISPR second-generation Red Puro DNMT3a 
To clone the DNMT3a-dCas9 module the large insert was split and cloned in two parts. The restriction sites are 
indicated in the figure. The numbers indicate the order of cloning. The dotted arrow indicates the cloning site. The 
continuous arrow shows the excision of the insert.  The right panel represents the final clone. 
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HDAC 
 
HDAC was taken from Addgene (ID 98591). The plasmid, being a Lentiviral vector, was partially 
compatible with LentiCRISPR second-generation RedPuro. Therefore, by sacrificing the presence 
of the RedPuro selection marker, we could directly sub-clone HDAC into our backbone, allowing 
the project to be completed in the allocated timeframe. Briefly, the strategy was to clone first the 
fragment going from NheI to BamHI restriction sites and then the fragment going from BamHI to 
PmeI restriction sites, removing the RedPuro cassette up to the 3’ LTR. The corresponding sites in 
the insert carry over the 3’end of dCas9-HDAC, an out-of-frame 2A peptide with Blasticidin coding 
sequence, followed by the 3’ LTR, which was excised from the backbone. The ligation reconstitutes 
a functional Lentivirus but the final product does not have a selection marker (Figure 12). A future 
project will reintroduce the RedPuro part (see discussion). 
 
 
 
Figure 12 - Design for LentiCRISPR second-generation HDAC 
To clone the HDAC-dCas9 module the large insert was split and cloned in two parts. The restriction sites are indicated 
in the figure. The numbers show the order of cloning. The dotted arrow indicates the cloning site. The continuous arrow 
points to the excision of the insert.  The right panel represents the final clone, which shows that the RedPuro is lost. 
 
 
KRAB 
 
The KRAB module was taken from Addgene (ID 60954). As for HDAC, it was possible to avoid 
PCR amplification and directly subclone KRAB-dCas9 into the LentiCRISPR second-generation 
RedPuro plasmid. The strategy, similarly to DNMT3a and HDAC projects, was to clone the insert 
by dividing it into two fragments, to be inserted sequentially. The first piece was flanked by 
EcoRV, BamHI and the second one by XbaI, EcoRV. However, XbaI was not available in the 
source plasmid, therefore we added it by creating an intermediate clone into the BlueScriptSK+, 
using BamHI and EcoRV restriction sites. In this manner, an XbaI site was added next to BamHI. 
After this intermediate clone, we excised EcoRV, XbaI and completed the project by ligating it to 
the plasmid carrying the first fragment (Figure 13).  
 
LentiCRISPR_v2_RedPuro 
LTR 
U6 
Spacer 
EFS Promoter 
 
 
RedPuro 
 
LTR 
AMPr 
spCas9	
LentiCRISPR_v2_HDAC 
LTR 
U6 
Spacer 
EFS Promoter 
 
 
LTR 
AMPr 
dCas9	HDAC	NheI	
PmeI	
spCas9	
NheI	PmeI	
HDAC-dCas9	(from	LentiCRISPRHDAC)	
	
BamHI	
BamHI	
1	
2	
RedPuro	
14		 	
 
 
Figure 13 - Design for LentiCRISPR second-generation RedPuro KRAB 
To clone the KRAB-dCas9 module the large insert was split in two parts. The first one was directly cloned into 
LentiCRISPR second-generation RedPuro (arrow 1). The second one was cloned into the intermediate vector 
BlueScriptSK+ (arrow 2). Subsequently, was excised using the external sites (XbaI, EcoRV) and cloned into the 
corresponding sites (arrow 3). The right panel represents the final clone. 
 
 
 
Discussion 
 
Pediatric sarcomas – there is still so much more to do 
 
Soft tissue and bone malignancies are frequently initiated by a specific chromosomal translocation, 
which constitutes a "signature" of the disorder and leads to the formation of a fusion gene, which in 
most cases encodes an aberrant transcription factor or transcriptional regulator (26,27). 
 
Recent studies have shown that some of these aberrant proteins affect the transcriptome by 
perturbing the chromatin state (2,4,5,11–16). The chemical modifications of the chromatin, 
including acetylation, methylation and phosphorylation of proteins and DNA, are commonly 
referred to as the epigenome, which constitute a control layer of genomic activity. 
 
Chromatin modifications are emerging as one of the most important pathways that lead to the 
transformation to cancer cells, which is dependent on the initial state of the cell of origin and the 
activity of the aberrant protein (26,27). In the case of Ewing sarcoma, the second most common 
malignancy of bone in children and young adults, permissive cells for the activity of the fusion 
protein have been identified as mesenchymal stem cells (MSCs). In these cells the aberrant fusion 
protein (EWS-FLI-1) behaves as an oncogene, modifies the chromatin structure of a range of 
promoters and enhancers and behaves as a pioneer factor (28). Nevertheless, mechanisms that 
determine how these modifications act are currently unknown and their elucidation will be critical 
toward developing more effective therapeutic management of Ewing sarcoma. 
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For several other translocation-dependent sarcomas, including synovial sarcoma, 
rhabdomyosarcoma and dermatofibrosarcoma, there is the same necessity to clarify how the 
perturbation of chromatin works in the context of tumor development. Different genes, including 
NKX2-2, SOX-2, EGR-2, and NPY-1R have been demonstrated to play a central role in this 
cascade (29–32). However, more data are necessary to better understand the interplay between these 
genes and their regulators.  
 
The discovery of nucleases that can target a specific region of a chromosome, including TALENs 
and CRISPRs, have opened new possibilities not only for genome manipulation but also for 
studying its regulatory control layer (7–9). In particular, CRISPR-Cas9 has emerged as a 
groundbreaking tool for its efficiency and simplicity and, by mutating the Cas9 nuclease and adding 
to it a chromatin modifier, can be used to modulate the epigenetic state of any region of interest.   
 
The purpose of this project is to improve a set of tools based on the above mentioned technology 
and create a system that will offer the possibility to investigate the effect of the translocations on 
chromatin regulation. Zhang et al. have created a second-generation CRISPR-Cas9 lentiviral vector, 
with a single delivery system containing the entire molecular machinery, which has been 
extensively used by the research community to edit the genome. On the other hand, the tools 
available for modifying the epigenome were not so advanced; therefore we combined this vector 
with the most commonly used epigenetic modifiers (2,4,5,11–16). We also introduced an additional 
feature to the plasmid, by exchanging the puromycin selection marker with a puromycin-red 
fluorescent fusion peptide. This modification should have the advantage of allowing virus titration 
by FACS analysis while maintaining the selection marker.   
 
 
Project’s challenges – every problem has a solution 
 
Perhaps unsurprisingly, the project has been extremely challenging. Even by using the most modern 
cloning technologies, which normally are very efficient, we faced several difficulties. The main 
problem we faced was the reduced number of clones as well as the extremely high background of 
false positives. 
 
We reasoned that several factors led to this effect: 
• The large size of both vector and insert makes cloning extremely challenging;  
• The presence of the LTR regions induce recombination events even in RecA defective 
bacterial strains; 
• Due to the presence of cryptic bacterial transcription activator inside the LTRs, the dCas9-
epigenetic modifier is expressed also in the bacterial cells leading to a toxic effect and 
negative selection activity. 
 
We had to develop a number of coping strategies to manage the above-mentioned difficulties:  
• When necessary, we addressed the problem of large inserts by splitting the cloning in two 
sequential steps; 
• We reduced the recombination risk by dephosphorylating the vector, therefore preventing 
inter-chain ligation events of the backbone, which is the primary cause of the deletion of 
repetitive regions (25); 
• We decreased the toxic effect of dCas9-epigenetic module by switching to a low plasmid 
copy number condition by setting the growing environment at 25oC; 
• Furthermore, to improve the general efficiency of the system, we used a special protocol 
(see Materials and methods) to make highly competent bacteria cells. 
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Overall, it was a learning experience to optimize to such a high degree the management of 
molecular cloning projects, which is an essential skill to have in a research laboratory.  
 
 
Future perspectives 
 
This is an ongoing project that will benefit from several further improvements: 
• Add more epigenetic modules, in particular EZH2 
• Modify VP64 to the second-generation activators (33,34) 
• Add a selection marker (RedPuro) to the HDAC vector 
 
The toolbox is ready to be used in our lab in new research projects focused on Ewing and synovial 
sarcoma. We already have designed several gRNAs to test (see Materials and methods). 
 
 
 
Materials and methods  
 
 
LentiCRISPR second-generation plasmid RedPuro cloning 
 
The RedPuro sequence was first amplified by plvmiRcontrol plasmid (BiOSETTIA), using the 
following primers: 
• RedPuroF 
(5’GGATCCGGCGCAACAAACTTCTCTCTGCTGAAACAAGCCGGAGATGTCGAAG
AGAATCCTGGACCGATGGTGAGCAAGGGCGAGGAG3’) 
• RedPuroR 
(5’AGTTCTTGCAGCTCGGTGAC3’) 
Subsequently the sequence was cloned in the pCRIIBlunt vector, according to the manufacturer’s 
instructions. From this intermediate vector the RedPuro was digested with BamHI, BsiWI and 
cloned into the corresponding sites of the LentiCRISPR second-generation plasmid. 
 
 
RedPuro transfection 
 
The functionality of the RedPuro vector was tested by transfecting HEK 293T, using the FuGENE 
system (Promega) with 2 µg of plasmid and a 3:1 ratio of liposomes:DNA, according to the 
manufacture instructions.  Puromycin resistance was assessed by selecting the cells at the 
concentration of 1 mg/mL G418. The fluorescence was tested on an epifluorescent microscope at 
20x magnification objective, using a mercury lamp to acquire the signal at 564 nm.  
 
 
PCR primers and conditions 
 
 
VP64 PCR amplification: 
 
The following primers were used to amplify a set of two overlapping amplicons: 
1. VP64XbaI (5’AATTCTAGAGGCCACCATGAAAAGGCCGGCGGCCACG3’) 
2. VP64A8116CF (5’GTGGCGGCCGCTGGCTCCGGACGGGCTGACGCATTGGAC3’) 
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3. VP64A8116CR (5’GCGTCAGCCCGTCCGGAGCCAGCGGCCGCCACCTTCCTC3’) 
4. VP64BamHI (5’GGCGGATCCTGTACAGTTAATCAGCATGTC3’) 
 
The first amplification was made using primers 1 and 3 with the following conditions: 30 cycles 
composed of 20’’ at 98°C, 30’’ at 65°C, 1’10’’ at 72°C, using a Phusion HF buffer (New England 
Biolabs).  
 
The second amplification was made using primers 2 and 4 with the following conditions: 30 cycles 
composed of 20’’ at 98°C, 30’’ at 60°C, 10’’ at 72°C, using a Phusion HF buffer (New England 
Biolabs). 
 
The final product was made using the external primers (1 and 4), harboring XbaI and BamHI, by 
gel purifying the set of the overlapping amplicons and using them as a template in a reaction with 
the following conditions: 30 cycles composed of 20’’ at 98°C, 30’’ at 65°C, 1’5’’ at 72°C, using a 
Phusion GC buffer (New England Biolabs).  
 
 
P300 PCR amplification: 
 
The following primers were used to amplify a set of two overlapping amplicons: 
1. P300SpeI (5’CCGACTAGTGCGCCATGGACTACAAAGAC3’) 
2. P300C5796TF (5’TGCGGAAGAAAGATGCATCAGATTTGTGTCCTTCACCATG3’) 
3. P300C5796R (5’ATCTCATGGTGAAGGACACAAATCTGATGCATCTTTCTTC3’) 
4. P300BglII (5’GCCAGATCTAGAAGCGTAGTCCGGAACGTCGTA3’) 
 
The first amplification was made using primers 1 and 3 with the following conditions: 30 cycles 
composed of 20’’ at 98°C, 30’’ at 60°C, 1’20’’ at 72°C, using a Phusion HF buffer (New England 
Biolabs).   
 
The second amplification was made using primers 2 and 4 with the following conditions: 30 cycles 
composed of 20’’ at 98°C, 30’’ at 60°C, 20’’ at 72°C, using a Phusion HF buffer (New England 
Biolabs).   
 
The final product was made using the external primers (1 and 4), harboring XbaI and BamHI, by 
gel purifying the set of the overlapping amplicons and using them as a template in a reaction with 
the following conditions: 30 cycles composed of 20’’ at 98°C, 30’’ at 56°C, 1’30’’ at 72°C, using a 
Phusion HF buffer (New England Biolabs).   
 
 
Tet1 PCR amplification: 
 
The following primers were used to amplify: 
1. Tet1XbaI (5’GGCTCTAGAGCCACCATGGACAAGAAGTATTCTATCG3’) 
2. Tet1BglII (5’GGCAGATCTGACCCAATGGTTATAGGGCCCCGCAACGTGTG3’) 
 
The reaction had the following conditions: 30 cycles composed of 20’’ at 98°C, 30’’ at 60°C, 1’45’’ 
at 72°C, using a Phusion HF buffer (New England Biolabs).   
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DNMT3a PCR amplification: 
 
The following primers were used to amplify: 
1. DNMT3aXbaI (5’CCATCTAGAGCCACCATGGACAAGAAGTATTCTATCG3’) 
2. DNMT3aBglII (5’CCTAGATCTCACACACGCAAAATACTCCTTC3’) 
 
The reaction had the following conditions: 30 cycles composed of 20’’ at 98°C, 30’’ at 60°C, 1’45’’ 
at 72°C, using a Phusion HF buffer (New England Biolabs). 
 
 
Fast ligation protocol 
 
The ligation was done for 10 minutes at 25°C using T4 ligase (New England BioLabs) with a 
homemade buffer containing PEG 8000 (Sigma) (35).  
 
 
Protocol for super-competent cells 
 
Stbl3 cells (Invitrogen) were made electrocompetent by using the established protocols (36,37). 
Briefly, a single colony cell was grown at 18°C for 36h in 500 mL of SOB medium. At the optical 
density of 0.25 at 600 nm the cells were harvested at 4°C, washed three times in a deionized water 
and resuspended in 7% DMSO in ultrapure water and stored at -80°C after snapshot freezing in 
liquid nitrogen. The competency achieved was 109 colonies/µg DNA. 
 
 
Electroporation protocol 
 
50 µl of competent cells were used in a 0.1 mm electroporation cuvette (BioRad) at 1.8 kV to 
transform the bacteria with our ligation product precipitated in butanol, washed with a 70% ethanol 
and resuspended in 4 µl of ultrapure water. 
 
 
Pre-screening cracking colonies protocol 
 
The cracking colonies method was based on the following protocol (38). Briefly, the colonies were 
first streaked on an agarose plate and growth overnight at 37°C.  Subsequently, 30 µL of the 
following buffer (Composition 2x: 20% sucrose, 200 mM NaOH, 120 mM KCl, 10 mM EDTA, 
0.5% SDS, 0.1% bromophenol blue) were diluted and pre-warmed at 37°C and aliquoted in a 384 
PCR plate (30 µL). A small portion of bacteria was collected with a 10 µL pipette-tip and washed in 
the buffer. After a 5’ incubation at 37°C and a 5’ incubation in ice, 15 µL of the samples were 
loaded onto an agarose gel containing 1:10’000 of Red gel (Biotium). 
 
 
Dephosphorylation protocol 
 
The dephosphorylation was done for 10 minutes at 37°C, followed by 5 minutes at 65°C to 
inactivate the enzyme. We used FastAP enzyme (Thermo Fisher Scientific) with the correspondent 
buffer FastAP buffer (Thermo Fisher Scientific). 
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Some gRNA oligonucleotides to test the toolbox 
 
Examples for DNMT3a and KRAB: 
 
• SOX2 gene 
gRNA1: CACCTTATCCATCTAACAGGTGGG (forward cloning oligonucleotide) 
AAACCCCACCTGTTAGATGGATAA (reverse cloning oligonucleotide) 
gRNA2: CACCGAAAATTGATTGAACCCAGG (forward cloning oligonucleotide) 
AAACCCTGGGTTCAATCAATTTTC (reverse cloning oligonucleotide) 
 
• EGR2 gene 
gRNA1: CACCCATCCAAATTAACATCAGTG (forward cloning oligonucleotide) 
AAACCACTGATGTTAATTTGGATG (reverse cloning oligonucleotide) 
gRNA2: CACCGACAGACAGGATAATATGGG (forward cloning oligonucleotide) 
AAACCCCATATTATCCTGTCTGTC (reverse cloning oligonucleotide) 
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